GRI Bio, Inc. develops cell based therapies for fibrotic and autoimmune diseases. Its programs are GRI-0621, GRI-0124, and GRI-0803. The company was founded by Marc Hertz, Vipin Kumar, and Albert Agro and is headquartered in La Jolla, CA.

Tianjin Tianshi Biological Development Co., Ltd., established on 1998-03-27, Business scope includes licensed projects:food production;Health food production;food sales;Cosmetic production;beverage production;Production of tea products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Development and application of technology without human stem cells,Development and application of human gene diagnosis and treatment technology);Manufacturing of daily chemical products;Sales of daily chemical products;Cosmetics Retail;Cosmetics Wholesale;Personal Hygiene Sales;General merchandise sales;Instrument Manufacturing;Instrument sales;Metal Structure Sales;Fabrication of Metal Structures;business training(Does not include education and training,Vocational skills training and other licensed training);Machinery and Equipment Leasing;Computer and communication equipment rental;Storage equipment rental service;Transportation equipment rental service;Office equipment rental service;Special equipment rental;Stationery equipment rental;Information Technology Consulting Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Not allowed to invest<Negative List for Foreign Investment Access>Fields where foreign investment is prohibited).

PANDICA is a medical device company, which developed a range of novel devices, . These devices help to address multiple unmet medical needs in diagnosis and treatment of life-threatening conditions of GI tract and pancreato-biliary systems. The unique feature of the devices is their ability to create an isolated area with controlled conditions (e.g. decompression) in GI tract, but at the saPandiCath®me time to maintain its connectivity and stimulate its function. This concept of "connects while isolating" enables prolonged use of the devices, essential for their many diagnostic and treatment applications. Application of PandiCath® and treatment methods based on its use will help save thousands of lives, reduce severity of the disease and cost of treating patients.

Lunan Pharmaceutical Group is an Integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc., initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product.

Techfields, Inc. is an American private company located in Princeton, NJ, that operates as clinical stage pharmaceutical company that develops medicines for inflammatory diseases. It was founded by Chongxi Yu and Lina Xu. Chongxi Yu is currently the CEO of the firm.

Medical Micro Cell Biotechnology (Guangzhou) Co., Ltd., established on 2018-10-31, Business scope includes biomedical technology research(human stem cells,Except for genetic diagnosis and treatment technology);Biotechnology Extension Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Development Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Consulting,communication service(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Transfer Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Health Sciences Program Research,to develop;Health Sciences Program Research Transfer;Technology Promotion of Research Results of Health Science Projects;Wholesale of cosmetics and hygiene products;Retailing of cosmetics and hygiene products;Technology intermediary service;Import and export(Except for commodities involving special management regulations on foreign investment access and licensing approval);Technology Import and Export

Tianjin Tianshi Life Source Co., Ltd., established on 2005-04-29, Business scope includes research,to develop,Production,Sales of health equipment,Daily chemical products,Disinfectant,food,And provide related technical consulting services,Product use training;Development of Bioengineering Technology,transfer,consultation service;Warehousing Services(Excluding flammable, explosive and dangerous chemicals),cargo handling.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

TaiwanJ Pharmaceuticals Co., Ltd. engages in new medical research activities. It offers drug testing, biotechnology services, and sale of western medicine. The company was founded by Sen Chou Wu on May 2, 2011 and is headquartered in Hsinchu, Taiwan.

Part of Lunan Pharmaceutical Group Co., Ltd., Shandong New Time Pharmaceutical Co. Ltd. is a Chinese company located in Linyi that manufactures pharmaceutical products.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Tianjin Tianshi Biological Engineering Co., Ltd., established on 1997-02-24, Business scope includes licensed projects:Health food production;food business;Import and export;Do dropshipping;Wholesale Publications;publication retail;Internet information service;Cosmetic production;Production of food detergents;road freight transport(Does not contain dangerous goods);Catering Services;Production of protective equipment for medical personnel(Class II medical device);Production of Class II Medical Devices;Production of medical masks.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Cosmetics Retail;Cosmetics Wholesale;Sales of hygiene products and single-use medical products;Manufacturing of daily necessities;Mechanical and electrical equipment manufacturing;Clothing and apparel wholesale;Clothing and apparel retail;Household Appliances Retail;Home Appliance Sales;Wholesale of hardware products;Hardware retail;Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;internet data service;Information Technology Consulting Services;Information system operation and maintenance services;Communication equipment sales;Wholesale of sporting goods and equipment;Sporting Goods and Equipment Retailing;Household Appliances Repair;Production of protective equipment for medical personnel(Ι class medical device);Production of Class I Medical Devices;Information Consulting Service(Not including licensing information consulting services);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;market survey(Does not include foreign investigations);Social Survey(Does not include foreign investigations);marketing planning;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Personal Hygiene Sales;General merchandise sales;needle textile sales;Wholesale of kitchenware, sanitary ware and daily sundries;Sales of building materials;Sales of building waterproof membrane products;Sales of building decoration materials;Conference and Exhibition Services;Sales of knitted textiles and raw materials.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.